Physician

Jeffrey Alexander Feinstein, M.D.

According to 2025 Medicare claims, Jeffrey Feinstein, M.D. (NPI: 1609867241) practices rheumatology in the San Antonio-New Braunfels, TX market, with the plurality of this provider's patient population coming from Bexar, TX. This provider's primary affiliated billing organization is RHEUMATOLOGY SOLUTIONS PLLC (NPI: 1891014205; TIN: 272571855) and primary practice location at 78239-1971. Feinstein is affiliated with the Main Street Rural Health Hickory ACO LLC (ACO ID: A5334) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Feinstein's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 572 traditional Medicare patients, billed 246,562 HCPCS/CPT codes, and received $2,560,673 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,026 prescription claims across 426 beneficiaries totaling $2,659,323 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2020 DME data shows 33 claims. Open Payments data shows 33 records totaling $2,173. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,380,312 to $2,659,323. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $7,732 and ending at $3,978.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	596	148,722	$1,688,528
2016	647	183,010	$2,269,612
2017	650	202,817	$2,530,928
2018	674	234,100	$3,080,090
2019	653	255,397	$3,338,985
2020	611	212,918	$3,024,055
2021	727	170,235	$2,484,026
2022	569	190,996	$2,094,723
2023	550	222,012	$2,164,015
2024	572	246,562	$2,560,673

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	338	4,302	$1,380,312
2016	407	4,425	$1,563,562
2017	442	4,813	$2,074,497
2018	454	5,070	$2,447,321
2019	436	4,828	$2,602,940
2020	430	4,679	$2,298,013
2021	451	4,607	$2,808,838
2022	434	4,644	$3,252,716
2023	414	4,153	$3,079,685
2024	426	4,026	$2,659,323

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	15	$744
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	35	$3,131
2020	N/R	33	$2,398
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	134	195	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	439	1,391	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	168	284	$65
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	120	770	$56
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	464	1,411	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	68	2,012	$694,783
Enbrel Sureclick	Etanercept	68	2,128	$550,111
Rinvoq	Upadacitinib	40	1,440	$299,889
Xeljanz Xr	Tofacitinib Citrate	35	1,050	$195,631
Orencia Clickject	Abatacept	31	868	$184,389

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	33	$2,173	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey Alexander Feinstein, M.D.?

Tedicare shows public-source Medicare data for Jeffrey Alexander Feinstein, M.D. (NPI 1609867241), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey Alexander Feinstein, M.D. have ACO affiliation data?

Jeffrey Alexander Feinstein, M.D. is shown with ACO affiliation data for Main Street Rural Health Hickory ACO LLC (MSSP, ACO ID A5334) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Jeffrey Alexander Feinstein, M.D.?

Jeffrey Alexander Feinstein, M.D. is linked to RHEUMATOLOGY SOLUTIONS PLLC (billing NPI 1891014205) in the available physician profile data.

Does Jeffrey Alexander Feinstein, M.D. have Open Payments data?

Jeffrey Alexander Feinstein, M.D. has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.